

## AMENDMENTS TO THE CLAIMS

1-25. (canceled)

26. (currently amended) A method of producing activated T cells ~~immune-activated cells~~ directed toward stratum corneum chymotrytic enzyme (SCCE), comprising the steps of:

exposing dendritic cells to a SCCE polypeptide that has an amino acid sequence selected from the group consisting of SEQ ID Nos. 31, 32, 33, 34, 35, 36, 80, 86, 99, and amino acid sequence encoded by the DNA of SEQ ID NO.30, thereby producing activated dendritic cells; and

exposing said activated dendritic cells to T cells, wherein said activated dendritic cells would present said SCCE polypeptide to said T cells, thereby producing activated T cells directed toward said SCCE polypeptide.

~~exposing dendritic cells to a stratum corneum chymotrytic enzyme protein or fragment thereof, wherein said stratum corneum chymotrytic enzyme protein or fragment thereof lacks stratum corneum chymotrytic enzyme protease activity, wherein said exposure to said stratum corneum chymotrytic enzyme protein or fragment thereof activates said dendritic cells, thereby~~

~~producing immune-activated cells directed toward stratum corneum  
chymotrytic enzyme.~~

27-29. (canceled)

30. (currently amended) The method of claim 26, wherein said dendritic cells are isolated from an individual prior to said exposure to said SCCE polypeptide, wherein said activated dendritic cells are reintroduced into said individual subsequent to said exposure.

31. (original) The method of claim 30, wherein said individual has a cancer, is suspected of having a cancer or is at risk of getting a cancer.

32-39. (canceled)